News
EVMN
7.63
-4.86%
-0.39
Evommune Price Target Cut to $25.00/Share From $28.00 by Needham
Dow Jones · 2d ago
Evommune Is Maintained at Buy by Needham
Dow Jones · 2d ago
Needham Maintains Buy on Evommune, Lowers Price Target to $25
Benzinga · 2d ago
RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN)
TipRanks · 2d ago
Analysts Offer Insights on NA Companies: Builders Firstsource (BLDR), Pelthos Therapeutics (PTHS) and Evommune, Inc. (EVMN)
TipRanks · 2d ago
Evommune, Inc. GAAP EPS of -$0.85 beats by $0.01
Seeking Alpha · 2d ago
Evommune Reports Third-Quarter Results and Pipeline Updates
TipRanks · 3d ago
Evommune Q3 EPS $(0.85) Misses $(0.84) Estimate
Benzinga · 3d ago
Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 3d ago
Weekly Report: what happened at EVMN last week (1102-1106)?
Weekly Report · 6d ago
Evommune to Present at Upcoming Investor Conferences
Barchart · 6d ago
Stifel Nicolaus Keeps Their Buy Rating on Evommune, Inc. (EVMN)
TipRanks · 11/05 21:47
At a glance: stocks gapping up premarket
Seeking Alpha · 11/05 12:25
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 11/05 12:05
Evommune Highlights EVO570 and Expanding Immunology Portfolio
TipRanks · 11/05 12:02
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
Barchart · 11/05 05:30
Evommune Expands Autoimmune Pipeline Through License and Financing
TipRanks · 11/04 23:30
Evommune Signs $20M License Deal With Hinova
Dow Jones · 11/04 22:50
Evommune raises $30M through private placement; shares up
Seeking Alpha · 11/04 22:31
Evommune prices 4.97M shares of common stock at $6.04 in private placement
TipRanks · 11/04 22:26
More
Webull provides a variety of real-time EVMN stock news. You can receive the latest news about EVOMMUNE INC through multiple platforms. This information may help you make smarter investment decisions.
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.